Symbol | Exchange | Currency |
|---|
RedHill Biopharma (NASDAQ:RDHL) Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the termination of RHB-204's[1] U.S. Phase...
RedHill Biopharma (NASDAQ:RDHL) Ltd. (Nasdaq: RDHL) today announced that it has received a written notification from the Nasdaq Stock Market LLC dated May 9, 2023 indicating that...
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of two new EU and U.S. patents for RHB-102...
RedHill Biopharma (NASDAQ:RDHL) RDHL announced data from a preclinical in vivo study, evaluating its COVID-19 drug Opaganib in kidney inflammation and fibrosis. Data from the study...
As it turns out, we’re not out of the woods yet in terms of the negative effects of the COVID-19 pandemic on the global economy. Last Monday, Goldman Sachs lowered its projections...
Investors in RedHill Biopharma (NASDAQ:RDHL) Ltd. RDHL need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2021 $5.00...
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Average | 40.000 (+1,718.182% Upside) |
| High | 40.000 |
| Low | 40.000 |
| Price | 2.200 |
| No. of Analysts | 1 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 124.37 | 125.04 | 123.30 | +1.00 | +0.81% | 24.25M | NASDAQ | |||
| 135.09 | 137.50 | 128.12 | -0.39 | -0.29% | 4.36M | NASDAQ | |||
| 0.205 | 0.22 | 0.201 | -0.0116 | -5.36% | 784.43K | NASDAQ | |||
| 0.68 | 0.70 | 0.63 | +0.03 | +5.04% | 1.35M | NASDAQ | |||
| 0.934 | 0.94 | 0.865 | +0.073 | +8.45% | 454.34K | NASDAQ | |||
| 0.237 | 0.237 | 0.237 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 5.10 | 5.14 | 5.06 | +0.050 | +0.99% | 1.40M | NASDAQ | |||
| 4.37 | 4.53 | 4.10 | -0.120 | -2.67% | 178.85K | NYSE | |||
| 1.81 | 1.81 | 1.81 | +0.010 | +0.56% | 1.34K | OTC Markets | |||
| 47.99 | 48.01 | 47.98 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 34.53 | 35.30 | 33.25 | +1.93 | +5.92% | 17.05M | NASDAQ | |||
| 0.11 | 0.12 | 0.11 | +0.0100 | +10.00% | 1.60K | OTC Markets | |||
| 293.96 | 294.98 | 275.76 | +0.17 | +0.06% | 3.68M | NASDAQ | |||
| 27.60 | 27.60 | 27.60 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 0.70 | 0.72 | 0.67 | +0.01 | +1.45% | 63.54K | NASDAQ |